106 related articles for article (PubMed ID: 27988324)
1. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus.
Schepp RM; Berbers GA; Ferreira JA; Reimerink JH; van der Klis FR
J Virol Methods; 2017 Mar; 241():15-23. PubMed ID: 27988324
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.
Herremans MM; Reimerink JH; Ras A; Van Der Avoort HG; Kimman TG; Van Loon AM; Conyn-Van Spaendonck MA; Koopmans MP
Clin Diagn Lab Immunol; 1997 Nov; 4(6):659-64. PubMed ID: 9384285
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus-binding inhibition ELISA based on specific chicken egg yolk antibodies as an alternative to the neutralization test.
Ivanov AP; Klebleyeva TD; Malyshkina LP; Ivanova OE
J Virol Methods; 2019 Apr; 266():7-10. PubMed ID: 30660606
[TBL] [Abstract][Full Text] [Related]
4. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
6. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
7. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
8. A simple and safe antibody neutralization assay based on polio pseudoviruses.
Jiang Z; Liu G; Guo-Yang L; Sun M; Xu K; Ying Z; Wang J; Li X; Li C
Hum Vaccin Immunother; 2019; 15(2):349-357. PubMed ID: 30273512
[TBL] [Abstract][Full Text] [Related]
9. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus.
Liu S; Song D; Bai H; Lu W; Dai X; Hao C; Zhang Z; Guo H; Zhang Y; Li X
J Med Virol; 2017 Dec; 89(12):2075-2083. PubMed ID: 28786502
[TBL] [Abstract][Full Text] [Related]
10. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
11. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines.
Zhaori G; Sun M; Ogra PL
J Infect Dis; 1988 Jul; 158(1):160-5. PubMed ID: 2839578
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.
Cuba IPV Study Collaborative Group
N Engl J Med; 2007 Apr; 356(15):1536-44. PubMed ID: 17429085
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
Sawyer LA; McInnis J; Albrecht P
Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an enzyme-linked immunosorbent assay based on binding inhibition for type-specific quantification of poliovirus neutralization-relevant antibodies.
Hashido M; Horie H; Abe S; Doi Y; Hashizume S; Agboatwalla M; Isomura S; Nishio O; Hagiwara A; Inouye S
Microbiol Immunol; 1999; 43(1):73-7. PubMed ID: 10100750
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
17. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
18. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
19. Poliovirus-binding inhibition ELISA for evaluation of immune response to oral poliovirus vaccine: a possible alternative to the neutralization test.
Ivanov AP; Dragunsky EM; Ivanova OE; Rezapkin GV; Potapova SG; Chumakov KM
Hum Vaccin; 2005; 1(3):102-5. PubMed ID: 17012865
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
